CL2012000097A1 - Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. - Google Patents

Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.

Info

Publication number
CL2012000097A1
CL2012000097A1 CL2012000097A CL2012000097A CL2012000097A1 CL 2012000097 A1 CL2012000097 A1 CL 2012000097A1 CL 2012000097 A CL2012000097 A CL 2012000097A CL 2012000097 A CL2012000097 A CL 2012000097A CL 2012000097 A1 CL2012000097 A1 CL 2012000097A1
Authority
CL
Chile
Prior art keywords
phenoxymethylpyrrolidine
treatment
pharmaceutical composition
serotonin
depression
Prior art date
Application number
CL2012000097A
Other languages
English (en)
Inventor
Dyke Priscilla Van
Eric L Stangeland
Adam Hughes
Daisuke R Saito
Jane Schmidt
Lori Jean Patterson
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43402084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2012000097A1 publication Critical patent/CL2012000097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos derivados de 3-fenoximetilpirrolidina; método de preparación; compuesto intermediario; composición farmacéutica; y uso en el tratamiento del dolor, trastornos depresivos, afectivos, entre otros.
CL2012000097A 2009-07-13 2012-01-12 Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. CL2012000097A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22507409P 2009-07-13 2009-07-13

Publications (1)

Publication Number Publication Date
CL2012000097A1 true CL2012000097A1 (es) 2012-08-10

Family

ID=43402084

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000097A CL2012000097A1 (es) 2009-07-13 2012-01-12 Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.

Country Status (18)

Country Link
US (3) US7994209B2 (es)
EP (1) EP2454234B1 (es)
JP (2) JP5826173B2 (es)
KR (1) KR20120070561A (es)
CN (2) CN102471258A (es)
AR (1) AR077662A1 (es)
AU (1) AU2010273645B2 (es)
CA (1) CA2767372A1 (es)
CL (1) CL2012000097A1 (es)
ES (1) ES2675791T3 (es)
IL (1) IL217049A (es)
MX (1) MX2012000685A (es)
NZ (1) NZ597433A (es)
RU (1) RU2535669C2 (es)
SG (1) SG177647A1 (es)
TW (1) TWI450718B (es)
WO (1) WO2011008666A2 (es)
ZA (1) ZA201200093B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
NZ605490A (en) * 2010-07-09 2014-10-31 Theravance Biopharma R & D Ip Llc Crystalline form of a 3-phenoxymethylpyrrolidine compound
US8471040B2 (en) 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
CN109674759A (zh) * 2019-01-22 2019-04-26 深圳信立泰药业股份有限公司 一种达泊西汀药物组合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203149A (en) 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
DE2549999A1 (de) 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US6518284B2 (en) 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
US6465458B1 (en) 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
WO2004017977A2 (en) 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
SI1638933T1 (sl) 2003-06-17 2008-10-31 Pfizer Derivati N-pirolidin-3-il-amida kot inhibitorji ponovnega privzema serotonina in noradrenalina
US7264788B2 (en) * 2003-11-26 2007-09-04 Cabot Corporation Fuel reformer catalyst and absorbent materials
EP1729754B1 (en) 2003-12-12 2008-07-02 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
US20070072859A1 (en) 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
GB0409744D0 (en) 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
US20090215857A1 (en) 2005-09-13 2009-08-27 Pfizer Products Inc. Therapeutic Pyrrolidines
EP1854785A1 (en) 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
EP2066630A1 (en) * 2006-08-23 2009-06-10 Pfizer Products Incorporated Piperidine derivatives
WO2010011811A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
AR075988A1 (es) 2009-04-09 2011-05-11 Lilly Co Eli Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
NZ605490A (en) * 2010-07-09 2014-10-31 Theravance Biopharma R & D Ip Llc Crystalline form of a 3-phenoxymethylpyrrolidine compound

Also Published As

Publication number Publication date
US20110009465A1 (en) 2011-01-13
US7994209B2 (en) 2011-08-09
TWI450718B (zh) 2014-09-01
JP5826173B2 (ja) 2015-12-02
EP2454234A2 (en) 2012-05-23
RU2535669C2 (ru) 2014-12-20
EP2454234B1 (en) 2018-04-11
US20150126577A1 (en) 2015-05-07
IL217049A (en) 2015-03-31
WO2011008666A2 (en) 2011-01-20
AR077662A1 (es) 2011-09-14
AU2010273645A1 (en) 2012-02-02
CA2767372A1 (en) 2011-01-20
RU2012104856A (ru) 2013-08-20
ZA201200093B (en) 2012-09-26
ES2675791T3 (es) 2018-07-12
SG177647A1 (en) 2012-02-28
KR20120070561A (ko) 2012-06-29
TW201106948A (en) 2011-03-01
NZ597433A (en) 2013-12-20
IL217049A0 (en) 2012-02-29
MX2012000685A (es) 2012-02-28
US20110257243A1 (en) 2011-10-20
CN105254552A (zh) 2016-01-20
US9227933B2 (en) 2016-01-05
CN102471258A (zh) 2012-05-23
WO2011008666A3 (en) 2011-03-10
JP2014218519A (ja) 2014-11-20
AU2010273645B2 (en) 2014-12-04
JP2012532930A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
EA201500431A1 (ru) Соединения боронатного эфира и его фармацевтические составы
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
UY35492A (es) Compuestos novedosos
CL2008000899A1 (es) Compuestos derivados de 3-imidazolil-indolilo, inhibidores de la interaccion entre p53 y mdm2 y/o mdm4; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades proliferativas.
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
DOP2016000253A (es) Nuevos compuestos
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
EA201170190A1 (ru) Фармацевтическая композиция, содержащая экстракт мозга свиньи